세계의 호흡기 의약품 시장 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)

The global market for Respiratory Drug was estimated to be worth US$ 51231 million in 2024 and is forecast to a readjusted size of US$ 74645 million by 2031 with a CAGR of 5.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Respiratory Drug cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Respiratory drug is a term used to describe a wide variety of medicines used to relieve, treat, or prevent respiratory diseases such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), or pneumonia. In 2024, global Respiratory drug production reached approximately 3851 m units, with an average global market price of around US$ 13.3 perunit.

The global population of respiratory disease patients continues to grow, with COPD, asthma, and chronic respiratory conditions representing a substantial patient base, driving strong demand for medications. Governments and regulators are introducing policies to support innovative drug development, bioequivalence evaluation of inhaled formulations, and chronic disease management, accelerating the launch of new drugs and improved formulations. Annual reports of leading pharmaceutical companies indicate significant year-on-year growth in inhaled therapies and biologics, with R&D investment and patent portfolios securing long-term market expansion. Brokerage research suggests that integration with digital health platforms and remote monitoring for personalized therapy could significantly increase market penetration over the next five years. Rising air pollution, aging populations, and chronic disease management needs sustain market growth, with innovative drugs and high-value formulations as key differentiators.

The respiratory drug sector faces high R&D costs, long development cycles, and strict regulatory requirements. Annual reports highlight that raw material price volatility and reliance on imported intermediates or APIs increase production risks. Adjustments to reimbursement lists and volume-based procurement policies may compress margins for generic drugs, while high-end innovative products depend on patient adherence and clinical evidence. Regulatory differences across countries complicate cross-border market entry. Intense competition requires new products to demonstrate clinical advantage, patient experience benefits, and differentiated services to secure repeat purchases and market share.

End-user demand is shifting toward precision, personalization, and full-cycle management. The growth of home chronic disease management and remote healthcare platforms is driving increased adoption of inhaled therapies, smart nebulizers, and personalized dosage medications. Healthcare institutions favor products integrated with electronic medical records, remote monitoring, and analytics platforms for efficacy tracking and adherence monitoring. Brokerage analyses indicate that combination therapies, adjustable dosages, and digital management capabilities will become key differentiators, while data analytics and remote follow-up enable long-term value in chronic disease management and patient education.

This report aims to provide a comprehensive presentation of the global market for Respiratory Drug, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Respiratory Drug by region & country, by Type, and by Application.

The Respiratory Drug market size, estimations, and forecasts are provided in terms of sales volume (M Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Drug.

Market Segmentation

By Company

• GSK
• AstraZeneca
• Boehringer Ingelheim
• Vertex
• Roche
• Novartis
• Teva
• Chiesi
• Mylan
• Sumitomo Dainippon
• Merck
• Beximco

Segment by Type

• Inhalable & Nasal Spray
• Oral
• Others

Segment by Application

• Hospital
• Drugs Store

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Respiratory Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Respiratory Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Respiratory Drug in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Respiratory Drug Product Introduction
• 1.2 Global Respiratory Drug Market Size Forecast
  • 1.2.1 Global Respiratory Drug Sales Value (2020-2031)
  • 1.2.2 Global Respiratory Drug Sales Volume (2020-2031)
  • 1.2.3 Global Respiratory Drug Sales Price (2020-2031)
• 1.3 Respiratory Drug Market Trends & Drivers
  • 1.3.1 Respiratory Drug Industry Trends
  • 1.3.2 Respiratory Drug Market Drivers & Opportunity
  • 1.3.3 Respiratory Drug Market Challenges
  • 1.3.4 Respiratory Drug Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Respiratory Drug Players Revenue Ranking (2024)
• 2.2 Global Respiratory Drug Revenue by Company (2020-2025)
• 2.3 Global Respiratory Drug Players Sales Volume Ranking (2024)
• 2.4 Global Respiratory Drug Sales Volume by Company Players (2020-2025)
• 2.5 Global Respiratory Drug Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Respiratory Drug Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Respiratory Drug Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Respiratory Drug
• 2.9 Respiratory Drug Market Competitive Analysis
  • 2.9.1 Respiratory Drug Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Respiratory Drug Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Drug as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Inhalable & Nasal Spray
  • 3.1.2 Oral
  • 3.1.3 Others
• 3.2 Global Respiratory Drug Sales Value by Type
  • 3.2.1 Global Respiratory Drug Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Respiratory Drug Sales Value, by Type (2020-2031)
  • 3.2.3 Global Respiratory Drug Sales Value, by Type (%) (2020-2031)
• 3.3 Global Respiratory Drug Sales Volume by Type
  • 3.3.1 Global Respiratory Drug Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Respiratory Drug Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Respiratory Drug Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Respiratory Drug Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Hospital
  • 4.1.2 Drugs Store
• 4.2 Global Respiratory Drug Sales Value by Application
  • 4.2.1 Global Respiratory Drug Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Respiratory Drug Sales Value, by Application (2020-2031)
  • 4.2.3 Global Respiratory Drug Sales Value, by Application (%) (2020-2031)
• 4.3 Global Respiratory Drug Sales Volume by Application
  • 4.3.1 Global Respiratory Drug Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Respiratory Drug Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Respiratory Drug Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Respiratory Drug Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Respiratory Drug Sales Value by Region
  • 5.1.1 Global Respiratory Drug Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Respiratory Drug Sales Value by Region (2020-2025)
  • 5.1.3 Global Respiratory Drug Sales Value by Region (2026-2031)
  • 5.1.4 Global Respiratory Drug Sales Value by Region (%), (2020-2031)
• 5.2 Global Respiratory Drug Sales Volume by Region
  • 5.2.1 Global Respiratory Drug Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Respiratory Drug Sales Volume by Region (2020-2025)
  • 5.2.3 Global Respiratory Drug Sales Volume by Region (2026-2031)
  • 5.2.4 Global Respiratory Drug Sales Volume by Region (%), (2020-2031)
• 5.3 Global Respiratory Drug Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Respiratory Drug Sales Value, 2020-2031
  • 5.4.2 North America Respiratory Drug Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Respiratory Drug Sales Value, 2020-2031
  • 5.5.2 Europe Respiratory Drug Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Respiratory Drug Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Respiratory Drug Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Respiratory Drug Sales Value, 2020-2031
  • 5.7.2 South America Respiratory Drug Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Respiratory Drug Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Respiratory Drug Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Respiratory Drug Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Respiratory Drug Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Respiratory Drug Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Respiratory Drug Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Respiratory Drug Sales Value, 2020-2031
  • 6.3.2 United States Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Respiratory Drug Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Respiratory Drug Sales Value, 2020-2031
  • 6.4.2 Europe Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Respiratory Drug Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Respiratory Drug Sales Value, 2020-2031
  • 6.5.2 China Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Respiratory Drug Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Respiratory Drug Sales Value, 2020-2031
  • 6.6.2 Japan Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Respiratory Drug Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Respiratory Drug Sales Value, 2020-2031
  • 6.7.2 South Korea Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Respiratory Drug Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Respiratory Drug Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Respiratory Drug Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Respiratory Drug Sales Value, 2020-2031
  • 6.9.2 India Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Respiratory Drug Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 GSK
  • 7.1.1 GSK Company Information
  • 7.1.2 GSK Introduction and Business Overview
  • 7.1.3 GSK Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 GSK Respiratory Drug Product Offerings
  • 7.1.5 GSK Recent Development
• 7.2 AstraZeneca
  • 7.2.1 AstraZeneca Company Information
  • 7.2.2 AstraZeneca Introduction and Business Overview
  • 7.2.3 AstraZeneca Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 AstraZeneca Respiratory Drug Product Offerings
  • 7.2.5 AstraZeneca Recent Development
• 7.3 Boehringer Ingelheim
  • 7.3.1 Boehringer Ingelheim Company Information
  • 7.3.2 Boehringer Ingelheim Introduction and Business Overview
  • 7.3.3 Boehringer Ingelheim Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Boehringer Ingelheim Respiratory Drug Product Offerings
  • 7.3.5 Boehringer Ingelheim Recent Development
• 7.4 Vertex
  • 7.4.1 Vertex Company Information
  • 7.4.2 Vertex Introduction and Business Overview
  • 7.4.3 Vertex Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Vertex Respiratory Drug Product Offerings
  • 7.4.5 Vertex Recent Development
• 7.5 Roche
  • 7.5.1 Roche Company Information
  • 7.5.2 Roche Introduction and Business Overview
  • 7.5.3 Roche Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Roche Respiratory Drug Product Offerings
  • 7.5.5 Roche Recent Development
• 7.6 Novartis
  • 7.6.1 Novartis Company Information
  • 7.6.2 Novartis Introduction and Business Overview
  • 7.6.3 Novartis Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Novartis Respiratory Drug Product Offerings
  • 7.6.5 Novartis Recent Development
• 7.7 Teva
  • 7.7.1 Teva Company Information
  • 7.7.2 Teva Introduction and Business Overview
  • 7.7.3 Teva Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Teva Respiratory Drug Product Offerings
  • 7.7.5 Teva Recent Development
• 7.8 Chiesi
  • 7.8.1 Chiesi Company Information
  • 7.8.2 Chiesi Introduction and Business Overview
  • 7.8.3 Chiesi Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Chiesi Respiratory Drug Product Offerings
  • 7.8.5 Chiesi Recent Development
• 7.9 Mylan
  • 7.9.1 Mylan Company Information
  • 7.9.2 Mylan Introduction and Business Overview
  • 7.9.3 Mylan Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Mylan Respiratory Drug Product Offerings
  • 7.9.5 Mylan Recent Development
• 7.10 Sumitomo Dainippon
  • 7.10.1 Sumitomo Dainippon Company Information
  • 7.10.2 Sumitomo Dainippon Introduction and Business Overview
  • 7.10.3 Sumitomo Dainippon Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 Sumitomo Dainippon Respiratory Drug Product Offerings
  • 7.10.5 Sumitomo Dainippon Recent Development
• 7.11 Merck
  • 7.11.1 Merck Company Information
  • 7.11.2 Merck Introduction and Business Overview
  • 7.11.3 Merck Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 Merck Respiratory Drug Product Offerings
  • 7.11.5 Merck Recent Development
• 7.12 Beximco
  • 7.12.1 Beximco Company Information
  • 7.12.2 Beximco Introduction and Business Overview
  • 7.12.3 Beximco Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.12.4 Beximco Respiratory Drug Product Offerings
  • 7.12.5 Beximco Recent Development

8 Industry Chain Analysis

• 8.1 Respiratory Drug Industrial Chain
• 8.2 Respiratory Drug Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Respiratory Drug Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Respiratory Drug Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer